drugset / Trial / NCT01893372
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if eltrombopag can help to control MDS. The safety of this drug will also be studied.
Timeline
- Start
- 2013-10
- Primary completion
- 2019-01-06
- Completion
- 2019-01-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 200 mg | Oral |
| Background | Azacitidine | Other / unclassified | — | — |
| Background | Decitabine | Small molecule | — | — |